Columvi
What Columvi is used for
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Columvi
- Active substance
- glofitamab
- Disease area
- Lymphoma, Large B-Cell, Diffuse
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX28
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Columvi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Columvi used for?
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.
What is the active substance in Columvi?
Columvi contains glofitamab.
Who makes Columvi?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU